ADMA Q1 2019 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-12.7% YoY

Gross Profit

-$6M-166.5% margin

Operating Income

-$13M-374.3% margin

Net Income

-$13M-370.3% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-13.0%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$637,263

Balance Sheet

Total Assets

$78M

Total Liabilities

$68M

Stockholders' Equity

$10M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$4M	-12.7%
Gross Profit	-$6M	-$8M	+28.3%
Operating Income	-$13M	-$17M	+20.1%
Net Income	-$13M	-$18M	+26.7%

Revenue Segments

Plasma Collection Centers

$2M61%

ADMA BioManufacturing

$1M38%

Corporate

$35,7081%